VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.69 on Thursday. The stock has a 50 day moving average of $0.69 and a 200-day moving average of $0.68. The firm has a market capitalization of $64.40 million, a PE ratio of -1.94 and a beta of 1.10. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.